Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

901 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
HIV MDR is still a relevant issue despite its dramatic drop over the years.
Armenia D, Di Carlo D, Flandre P, Bouba Y, Borghi V, Forbici F, Bertoli A, Gori C, Fabeni L, Gennari W, Pinnetti C, Mondi A, Cicalini S, Gagliardini R, Vergori A, Bellagamba R, Malagnino V, Montella F, Colafigli M, Latini A, Marocco R, Licthner M, Andreoni M, Mussini C, Ceccherini-Silberstein F, Antinori A, Perno CF, Santoro MM. Armenia D, et al. Among authors: antinori a. J Antimicrob Chemother. 2020 May 1;75(5):1301-1310. doi: 10.1093/jac/dkz554. J Antimicrob Chemother. 2020. PMID: 31976521
Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study.
Mussini C, Pezzotti P, Govoni A, Borghi V, Antinori A, d'Arminio Monforte A, De Luca A, Mongiardo N, Cerri MC, Chiodo F, Concia E, Bonazzi L, Moroni M, Ortona L, Esposito R, Cossarizza A, De Rienzo B. Mussini C, et al. Among authors: antinori a. J Infect Dis. 2000 May;181(5):1635-42. doi: 10.1086/315471. Epub 2000 May 15. J Infect Dis. 2000. PMID: 10823763 Clinical Trial.
Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART.
Monforte Ade A, Bugarini R, Pezzotti P, De Luca A, Antinori A, Mussini C, Vigevani GM, Tirelli U, Bruno R, Gritti F, Piazza M, Chigiotti S, Chirianni A, De Stefano C, Pizzigallo E, Perrella O, Moroni M; ICONA (Italian Cohort of Naive for Antiretrovirals) Study Group. Monforte Ade A, et al. Among authors: antinori a. J Acquir Immune Defic Syndr. 2001 Oct 1;28(2):114-23. doi: 10.1097/00042560-200110010-00002. J Acquir Immune Defic Syndr. 2001. PMID: 11588504
Factors related to virologic failure among HIV-positive injecting drug users treated with combination antiretroviral therapy including two nucleoside reverse transcriptase inhibitors and nevirapine.
Zaccarelli M, Barracchini A, De Longis P, Perno CF, Soldani F, Liuzzi G, Serraino D, Ippolito G, Antinori A. Zaccarelli M, et al. Among authors: antinori a. AIDS Patient Care STDS. 2002 Feb;16(2):67-73. doi: 10.1089/10872910252806117. AIDS Patient Care STDS. 2002. PMID: 11874638
Key questions in antiretroviral therapy: Italian Consensus Workshop (2005).
Carosi G, Torti C, Andreoni M, Angarano G, Antinori A, Bonora S, Borderi M, Castagna A, Castelli F, Cauda R, Chiodo F, D'arminio-Monforte A, De Luca A, Di Perri G, Dianzani F, Filice G, Galli M, Lazzarin A, Maggiolo F, Maserati R, Mazzotta F, Moroni M, Perno CF, Vullo V. Carosi G, et al. Among authors: antinori a. J Antimicrob Chemother. 2006 Jun;57(6):1055-64. doi: 10.1093/jac/dkl113. Epub 2006 Apr 10. J Antimicrob Chemother. 2006. PMID: 16606637
Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone.
Bongiovanni M, Gianotti N, Chiesa E, Nasta P, Cicconi P, Capetti A, di Biagio A, Matti A, Tirelli V, Marconi P, de Luca A, Mussini C, Gatti F, Zaccarelli M, Abeli C, Torti C, Antinori A, Castagna A, d'Arminio Monforte A. Bongiovanni M, et al. Among authors: antinori a. Infection. 2007 Dec;35(6):451-6. doi: 10.1007/s15010-007-7120-x. Epub 2007 Nov 21. Infection. 2007. PMID: 18034204 Clinical Trial.
901 results